Animal Care Secures New Sale in Germany, Expanding Support for Veterinary Clinics Treating Domestic Animals
CSP
2 min read
17

Animal Care Secures New Sale in Germany, Expanding Support for Veterinary Clinics Treating Domestic Animals

November 1, 2024
0

Reading Time: 2 minutes Scandinavian ChemoTech’s Animal Care is pleased to announce a recent sale of its vetIQure™ TSE device with treatment kits to veterinary practice Christoph Sonntag in Germany specializing in the care of domestic animals, with a focus on dogs and cats.

Continue Reading
Invitation to Corem’s capital market day 2024
CSP
2 min read
18

Invitation to Corem’s capital market day 2024

November 1, 2024
0

Reading Time: 2 minutes   Corem invites institutional investors, analysts and financial media to a capital market day on 20 November 2024. The capital market day aims to provide an update on Corem’s operations and strategic direction. During the day, there will also be a

Continue Reading
CSP
2 min read
16

Crunchfish publishes interim report Q3 2024

November 1, 2024
0

Reading Time: 2 minutes Today, Crunchfish AB (“Crunchfish”) publishes the company’s interim report for the third quarter and nine months of 2024. Below is a brief summary of the report. Group financials 2024-07-01 2024-09-30 2023-07-01 2023-09-30 2024-01-01 2024-09-30 2023-01-01 2023-09-30 Net sales (SEK) 273 773

Continue Reading
CSP
2 min read
18

InCoax Networks AB Interim Report, July – September 2024

November 1, 2024
0

Reading Time: 2 minutes The collaboration with Nokia is entering a new phase with increasing market activities among operators in the U.S., Europe, and Asia. The highly promising FWA market opens opportunities for volume sales to new customer segments with the existing product portfolio. Financial

Continue Reading
CSP
3 min read
18

Panoro Energy – Block G Infill Well Onstream Offshore Equatorial Guinea

November 1, 2024
0

Reading Time: 2 minutes Oslo, 1 November 2024 – Panoro Energy ASA (“Panoro” or the “Company”) is pleased to announce that the C-45 infill well has successfully been put onstream by the Block G operator, Trident Energy, at an initial gross rate in excess of

Continue Reading
CSP
2 min read
12

Aker Solutions ASA: Notice of Extraordinary General Meeting

November 1, 2024
0

Reading Time: < 1 minute November 1, 2024 – An extraordinary general meeting of Aker Solutions ASA will be held on Friday November 22, 2024, at 12:30 CET. The general meeting will be held as a digital meeting only, with no physical attendance for shareholders.

Continue Reading
CSP
3 min read
23

Sileon divests Payments business area

November 1, 2024
0

Reading Time: 2 minutes Read original Sileon AB (publ) (“Sileon” or the “Company”) has today entered into an agreement with Avarda a part of TF Bank AB (publ) (the “Purchaser”) whereby the Company’s assets related to the business area Payments (“Payments”) are divested. The sale of

Continue Reading
CSP
1 min read
21

#24-375 Listing of Derivatives at NGM

November 1, 2024
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
37

Nordea Bank Abp: Repurchase of own shares on 31.10.2024

November 1, 2024
0

Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares31.10.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 31.10.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average

Continue Reading
CSP
6 min read
35

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

October 31, 2024
0

Reading Time: 4 minutes Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand

Continue Reading